News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Syneron Medical Ltd. (ELOS) Announces International Launch of eLase(TM) Laser Hair Removal System


11/9/2011 9:16:05 AM

YOKNEAM, ISRAEL--(Marketwire - November 08, 2011) - Syneron Medical Ltd. (NASDAQ: ELOS), the leading global aesthetic device company, announced today the International launch of the eLase™ with Motif™ laser hair removal system. The eLase system will be unveiled at CosmoProf Asia 2011, November 9-11, 2011. The eLase system has received CE Mark approval from the European Union and is available in select European and Asian markets.

The eLase system combines Syneron's proprietary elos bi-polar radio frequency (RF) energy with diode laser energy. This synergistic energy combination allows the system to utilize less optical energy during treatments, increasing patient safety for all skin types. The system features the new Motif LHR hair removal applicator with Motif mode that leverages the energy combination to allow high frequency, lower energy treatments that are virtually pain free with far shorter treatment times than competitive devices. The system also includes a new Motif IR applicator that can be used for fractional facial rejuvenation procedures with zero patient downtime, expanding the capabilities of the eLase system beyond hair removal procedures.

Louis P. Scafuri, Chief Executive Officer of Syneron Medical, said, "The eLase builds upon Syneron and Candela's proven track record of best-in-class hair removal systems with a next-generation platform designed to further enhance the patient experience. The unique combination of our elos technology allows for selective and deep dermal penetration, providing highly effective and safe hair removal treatments for patients of all skin types. In addition, the eLase features many ease-of-use and patient comfort enhancements, including faster treatment times, a new pain free mode, contact cooling and intra-procedure dermal monitoring."

Mr. Scafuri further added, "In addition to the hair removal mode, the system also has an optional Motif IR applicator that allows the practice to leverage the eLase to offer fractional skin rejuvenation procedures with the same platform and same safety profile across skin types. The eLase system is available through our direct sales force and distribution partners in Europe and Asia."

About Cosmoprof Asia 2011
Cosmoprof Asia is the leading business-to-business beauty trade show event in Asia. Exhibits are divided into five themed sectors that cover the entire spectrum of the beauty industry. This exhibition features the latest trends and products from within all segments of the beauty and wellness industry. Strong International participation is confirmed by the presence of national and group pavilions, providing a global perspective on emerging trends.

About Syneron Medical Ltd.
Syneron Medical Ltd. (NASDAQ: ELOS) is the leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under two distinct brands, Syneron and Candela. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and manufacturing operations in the US. The Company markets, services and supports its products in 90 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.


Investor Contacts:

Asaf Alperovitz
Chief Financial Officer
+ 972 73 244 2283
Email: Email Contact

Zack Kubow
The Ruth Group
646-536-7020
Email: Email Contact


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES